Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Vancomycin Stories

2013-03-21 00:20:46

AUSTIN, TX and TORONTO, March 20, 2013 /PRNewswire/ - Affinium Pharmaceuticals announced today that its Phase 2a clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections (ABSSSI) demonstrated excellent efficacy and safety data, marking a significant proof-of-concept milestone for Affinium's first-in-class, novel antibiotic targeted against bacterial fatty acid biosynthesis inhibition (FabI inhibitors). Barry Hafkin, MD, Chief Medical Officer of...

2013-03-14 00:20:49

AUSTIN, TX and TORONTO, March 13, 2013 /PRNewswire/ - Affinium Pharmaceuticals announced today the expansion of its leadership team with the appointment of two senior biotech and pharmaceutical executives to its leadership team:  Ed Mascioli, M.D. is appointed Chief Executive Officer (CEO), and Mr. Robert (Bob) Radie is appointed to the Board of Directors. Dr. Mascioli is an experienced pharmaceutical and venture executive, and held prior positions as a senior executive at...

2013-03-12 12:23:05

Antimicrobial Copper Products in Hospitals Should Be Considered as a Response to CDC's Latest Warning on Lethal Bacteria NEW YORK, March 12, 2013 /PRNewswire/ -- Deadly bacterial infections are on the rise in American hospitals, as antibiotics are being overcome by germs known as carbapenem-resistant Enterobacteriaceae (CRE). While many antibiotics have failed to treat bacteria such as CRE, Antimicrobial Copper has been proven to continuously kill greater than 99.9% of bacteria* that...

2013-02-26 08:28:51

AUSTIN, Texas, Feb. 26, 2013 /PRNewswire/ -- Savara Pharmaceuticals today announced the formation of its Clinical Advisory Board to provide clinical guidance to the company as it advances the development of its lead product, AeroVanc(TM) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in patients with cystic fibrosis (CF). The Clinical Advisory Board is comprised of five prominent thought leaders within the cystic fibrosis and infectious disease...

2013-02-14 08:29:00

JERSEY CITY, N.J., Feb. 14, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the February 2013 Journal of the American Geriatrics Society published results from a multivariate analysis demonstrating that advancing age is a predictor of deterioration in treatment outcomes in patients with Clostridium difficile infection (CDI). The analysis was performed using data from two large, randomized Phase 3 clinical studies that compared the efficacy of...

2013-01-07 08:28:55

EXTON, Pa., Jan. 7, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will provide an overview of the company's business, including additional maribavir clinical trial data, during the 31(st) Annual J.P. Morgan Healthcare Conference. The presentation will be webcast live at 6:30 P.M. ET (3:30 P.M. PT) on Tuesday, January 8, 2013 and may be accessed via the company's website at...

2012-12-14 08:24:37

CHAPEL HILL, N.C., Dec. 14, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the initiation of its Phase 2 clinical trial of CEM-102 in patients with prosthetic joint infections (PJIs). CEM-102 is the company's loading dose formulation of fusidic acid, an orally-active anti-staphylococcal agent with a long history of...

2012-11-13 08:34:44

AUSTIN, Texas, Nov. 13, 2012 /PRNewswire/ -- Savara Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to AeroVanc(TM)( )(vancomycin hydrochloride inhalation powder) for the treatment of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis (CF) patients. Orphan drug designation qualifies a company for several benefits, including the potential for market exclusivity, development...

2012-10-24 07:32:22

HAYWARD, Calif. and SHANGHAI, Oct. 24, 2012 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, and Shanghai Zhangjiang Biomedical Industry Venture Capital today announced the establishment of Shanghai MengKe Pharmaceuticals, Inc., a joint venture formed to fund the development and commercialization of MRX-I for the Chinese market. MRX-I is a novel, oral oxazolidinone antibiotic targeting infections due to...

2012-10-09 07:26:40

DURHAM, N.C., Oct. 9, 2012 /PRNewswire/ -- A first of its kind study conducted by the University of Iowa Carver College of Medicine found standard control curtains were 8 times more likely to be contaminated with the superbug vancomycin resistant enterrococus (VRE) than experimental PurThread privacy curtains which only had 1 positive VRE culture during the entire study. Additionally, the median time to first contamination of PurThread curtains took seven times longer than control curtains....


Latest Vancomycin Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »